NCT01418352 - Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2011

Primary Completion Date

March 12, 2014

Study Completion Date

March 12, 2014

Conditions

Tourette's Disorder

Interventions

DRUG

Aripiprazole

Aripiprazole tablets once weekly for 8 weeks.

DRUG

Placebo

Aripiprazole matching-placebo once-weekly for 8 weeks.

Trial Locations (35)

1431

Sofia

7004

Rousse

9010

Varna

11030

Manhasset

21005

Vinnytsia

22903

Charlottesville

30308

Atlanta

30329

Atlanta

30625

Hanover

32610

Gainesville

33126

Miami

36006

Poltava

36303

Dothan

52074

Aachen

54601

La Crosse

60612

Chicago

61068

Kharkiv

61153

Kharkiv

68131

Omaha

73112

Oklahoma City

73488

Stepanovka

80336

München

83008

Donetsk

89075

Ulm

91045

Luhansk

94143

San Francisco

200620

Craiova

400660

Cluj-Napoca

700282

Iași

45229-3039

Cincinnati

01307

Dresden

041914

Bucharest

01030

Kyiv

03049

Kyiv

04209

Kyiv

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY